I reiterate a 'Sell' rating on Intuitive Surgical with a fair value of $350 per share due to its hefty valuation. The Da Vinci 5 robot rollout in mid-2025 is a major catalyst, with significant growth ...

Intuitive Surgical, with its Da Vinci robots, enjoys a great competitive position in minimally invasive surgery, driven by $6 billion in R&D and first-mover advantage. The business model, with 84% ...

Striving to stand out in the competitive humanoid robotics market, Polish-frim Clone Robotics has unveiled its first full-scale humanoid robot, Clone Alpha. The humanoid integrates synthetic organs ...